Table 3.

Multivariable Cox regression analysis of the impact of different variables on the leukemia-free survival and overall survival of patients with myelodysplastic syndromes/neoplasms.

Note: Only 17 patients (2.7%) were categorized as IPSS-M very low risk and there was no inter-group difference between IPSS-M very low and low risk subgroups in both OS and LFS; accordingly, we put IPSS-M very low and low groups together.

CI confidence interval, HR hazard ratio, HSCT allogeneic hematopoietic stem cell transplantation, h hypoplastic, IPSS-M molecular international prognostic scoring system, LFS leukemia-free survival, MDS myelodysplastic syndromes/neoplasms, OS overall survival.

P values of <0.05 are statistically significant.

*As continuous variables analysis.

^†Low-risk MDS included MDS with del(5q), MDS with mutated SF3B1, MDS, NOS with MLD.

^‡MDS patients with EB and blast percentage < 5% in peripheral blood.

^§MDS/AML with MDS-related gene mutations, MDS-related cytogenetic abnormalities, or not otherwise specified. Patients with MDS with EB and blast percentage ≥ 5% in peripheral blood were included in this group.

^¶MDS or MDS/AML with mutated TP53, defined by International Consensus Classification.